1. Home
  2. BESS vs LPCN Comparison

BESS vs LPCN Comparison

Compare BESS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BESS

Bimergen Energy Corporation Common Stock

N/A

Current Price

$4.13

Market Cap

16.6M

Sector

N/A

ML Signal

N/A

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$2.29

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BESS
LPCN
Founded
1998
1997
Country
United States
United States
Employees
3
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.6M
19.1M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
BESS
LPCN
Price
$4.13
$2.29
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
239.5K
94.4K
Earning Date
03-31-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
N/A
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$92.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$1.81
52 Week High
$5.00
$12.37

Technical Indicators

Market Signals
Indicator
BESS
LPCN
Relative Strength Index (RSI) 63.96 35.38
Support Level $2.03 $2.16
Resistance Level N/A $2.50
Average True Range (ATR) 0.59 0.10
MACD 0.13 0.11
Stochastic Oscillator 70.71 42.11

Price Performance

Historical Comparison
BESS
LPCN

About BESS Bimergen Energy Corporation Common Stock

Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: